Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

13D Filing: Adage Capital Management and Inotek Pharmaceuticals Corp (ITEK)

Published on October 5, 2017 at 2:20 pm by Insider Monkey Staff in Hedge Funds

Page 1 of 13

Inotek Pharmaceuticals Corp (NASDAQ:ITEK): Phill Gross And Robert Atchinson’s Adage Capital Management filed an amended 13D.

You can check out Adage Capital Management’s latest holdings and filings here.

Please follow Adage Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Adage Capital Management or update its stock holdings.

Follow Phill Gross's Adage Capital Management

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Adage Capital Partners	0	1,500,000	0	1,500,000	1,500,000	5.55%
Adage Capital Partners GP	0	1,500,000	0	1,500,000	1,500,000	5.55%
Adage Capital Advisors	0	1,500,000	0	1,500,000	1,500,000	5.55%
Robert Atchinson	0	1,500,000	0	1,500,000	1,500,000	5.55%
Phillip Gross	0	1,500,000	0	1,500,000	1,500,000	5.55%

Follow Phill Gross's Adage Capital Management

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 13 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. )*

Inotek Pharmaceuticals Corporation
(Name of Issuer)

Common Stock, par value $0.01 per share
(Title of Class of Securities)

45780V102
(CUSIP Number)

Robert Atchinson
Adage Capital Partners GP, L.L.C.
200 Clarendon Street, 52nd Floor
Boston, MA 02116
(617) 867-2800
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

September 26, 2017
(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule
13d-1(f) or Rule 13d-1(g), check the following box. [ ]

(Page 1 of 13 Pages)

______________________________

* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or
otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)

Follow Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 13

NASDAQ:ITEK SEC 13D Filing Adage Capital Management Inotek Pharmaceuticals Corp (ITEK)